Q-omics provides the consensus-scored PRPS1 profile across patient tissues and cancer cell-line models. PRPS1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PRPS1 is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, PRPS1 RNA expression shows 19,384 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, HNSC, and UVM as cancer lineages where PRPS1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRPS1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRPS1 survival associations across molecular data types. PRPS1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (3) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRPS1 RNA expression–survival associations across cancer types. High PRPS1 expression shows unfavorable associations in MESO, KICH, HNSC and SARC, but favorable associations in KIRC and OV. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PRPS1 RNA expression.
This table summarizes PRPS1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PRPS1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRPS1 shows lower tumor expression in THCA and KICH and higher tumor expression in HNSC, COAD, KIRC and LUAD. The HNSC box plot shows higher PRPS1 RNA expression in tumor versus normal tissue (log2 FC = +1.622, t-test p < 0.001).
This table shows molecular features associated with PRPS1 in patient tissues and cancer cell lines. In patient samples, PRPS1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, PRPS1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and CNS.
